目的设计并合成一系列新的双芳环酰胺类和苯并咪唑类衍生物,对其抗柯萨奇病毒活性进行初步评价。方法考察双芳环中A环上3位和4位取代基、B环上取代基及双芳环间的酰胺链对活性的影响,并采用细胞病变程度(CPE)方法测定了目标化合物对柯萨奇病毒的抑制活性。结果与结论共合成了10个双芳环酰胺类和4个苯并咪唑类化合物,其中,11个目标化合物(1a~1c、2a-2d、3b、4b~4d)未见文献报道,所有目标化合物的结构经。H—NMR和ESI-MS确证。该类化合物抗柯萨奇病毒活性的初步筛选结果显示,多个化合物对柯萨奇病毒B3亚型具有抑制活性,其中化合物1c表现出最强的抑制活性,选择性指数达到106.38。
Coxsackievirus B3 ( CVB3 or CoxB3 ) is the most common cause of acute and chronic viral myocarditis, mostly in children. However, there is current no drug approved for the treatment of CVB3. Based on our preliminary study, compounds IMB-26 and A-1 which have the substituted benzamide skeleton structures exhibited broad-spetrum antiviral effects. In this paper, a series of N-phenylbenzamide and benzimidazole compounds were synthesized and evaluated for their antiviral activity against CoxB3. Their structures were identified by 1H-NMR,~3C-NMR and ESI-MS ,and the anti-CoxB3 activity was screened by CPE method. The preliminary biological results showed that several compounds (lc ,2b ,3a and 3b) exhibited considerable anti-CoxB3 activity with the IC50 values lower than 5.00 μmol.L^-1. Especially, compound lc displayed the highest anti-CoxB3 activity and the selectivity index(SI) was 106. 38. Preliminary structure-activity relationships revealed that the propionyl amino group at the C3-position on the benzene ring A and the amide linker between two benzene rings were favored for anti-CoxB3 activity.